Compare · AVTR vs PRPO
AVTR vs PRPO
Side-by-side comparison of Avantor Inc. (AVTR) and Precipio Inc. (PRPO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVTR and PRPO operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- AVTR is the larger of the two at $7.81B, about 184.5x PRPO ($42.3M).
- PRPO has been more active in the news (3 items in the past 4 weeks vs 2 for AVTR).
- AVTR has more recent analyst coverage (25 ratings vs 0 for PRPO).
- Company
- Avantor Inc.
- Precipio Inc.
- Price
- -
- -
- Market cap
- $7.81B
- $42.3M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 2
- 3
- Recent ratings
- 25
- 0
Avantor Inc.
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, and clinical trial kits. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Precipio Inc.
Precipio, Inc., a cancer diagnostics and reagent technology company, provides diagnostic products and services in the United States oncology market. Its product consists of clinical diagnostic services. The company's clinical diagnostic services focus on the diagnosis of different hematopoietic or blood-related cancers to oncologists. Its cytogenetics media IV-Cell enables laboratories to arrive at more accurate results; HemeScreen panel enables hospitals and laboratories to run an important genetic mutation test; and ICE-COLD-PCR enables detection of abnormalities in blood samples. The company also operates a cancer diagnostic laboratory located in New Haven, Connecticut. It sells ICE-COLD-PCR technology kits to bio-pharma customers, clinical research, HemeScreen, and COVID-19 antibody tests. The company serves oncologists, hospitals, reference laboratories, physician-office labs, and pharma and biotech companies. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment, such as the Yale School of Medicine, Harvard's Dana-Farber Cancer Institute, and the University of Pennsylvania. The company is based in New Haven, Connecticut.
Latest AVTR
- Avantor Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Avantor's® NuSil® Brand Expands Partnership with the Population Council to Develop Long-Acting HIV Prevention Product
- Avantor® to Report Second Quarter 2026 Earnings on Wednesday, July 29, 2026
- Bernstein resumed coverage on Avantor with a new price target
- President, VWR Dist. & Servs. Walker Corey covered exercise/tax liability with 3,010 shares, decreasing direct ownership by 0.78% to 384,535 units (SEC Form 4) to cover taxes
- Wolfe Research resumed coverage on Avantor with a new price target
- SEC Form SD filed by Avantor Inc.
- Avantor® Announces Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory
- RBC Capital Mkts resumed coverage on Avantor with a new price target
- Avantor Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
Latest PRPO
- Director Valauri Christina Rizopoulos was granted 108 shares, increasing direct ownership by 2% to 5,628 units (SEC Form 4)
- Director Cossman Jeffrey was granted 416 shares, increasing direct ownership by 3% to 16,549 units (SEC Form 4)
- Director Cohen David Seth was granted 520 shares, increasing direct ownership by 0.95% to 55,199 units (SEC Form 4)
- Precipio Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting
- Precipio to Present at the Planet MicroCap Las Vegas
- Director Sandberg Richard A sold $22,517 worth of shares (900 units at $25.02) (SEC Form 4)
- Director Sandberg Richard A sold $77,784 worth of shares (3,134 units at $24.82), decreasing direct ownership by 20% to 8,142 units (SEC Form 4)
- Precipio Announces Q1 2026 Financial Results
- SEC Form 10-Q filed by Precipio Inc.